Erbitux: Phase I/II data

In an open-label, international Phase I/II trial of Erbitux plus FUFOX chemotherapy (5-fluorouracil, folinic acid and oxaliplatin) in 38 evaluable patients, 52.6% patients had a partial response, 23.7...